AutomedicationFrancoV1, Main, Exploration, bibRecord, 000831

Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.

Identifieur interne : 000831 ( Main/Exploration ); précédent : 000830; suivant : 000832

Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.

Auteurs : Clare Bradley [Royaume-Uni] ; Eveline Eschwège [France] ; Pedro De Pablos-Velasco [Espagne] ; Klaus G. Parhofer [Allemagne] ; Dominique Simon [France] ; Hans Vandenberghe [Belgique] ; Linda Gönder-Frederick [États-Unis]

Source :

Diabetes care [ 1935-5548 ] ; 2018.

RBID : pubmed:29183910

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Anxiété (épidémiologie), Anxiété (étiologie), Autorapport (MeSH), Diabète de type 2 (complications), Diabète de type 2 (psychologie), Diabète de type 2 (thérapie), Diabète de type 2 (épidémiologie), Femelle (MeSH), Glycémie (métabolisme), Humains (MeSH), Hypoglycémie (psychologie), Hypoglycémie (épidémiologie), Hypoglycémie (étiologie), Hémoglobine A glycosylée (métabolisme), Internationalité (MeSH), Mesures des résultats rapportés par les patients (MeSH), Mâle (MeSH), Qualité de vie (MeSH), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Études transversales (MeSH).
MESH :
- métabolisme : Diabète de type 2, Glycémie, Hémoglobine A glycosylée.
- psychologie : Diabète de type 2, Hypoglycémie.
- thérapie : Diabète de type 2.
- épidémiologie : Anxiété, Diabète de type 2, Hypoglycémie.
- étiologie : Anxiété, Hypoglycémie.
- Adulte, Adulte d'âge moyen, Autorapport, Femelle, Humains, Internationalité, Mesures des résultats rapportés par les patients, Mâle, Qualité de vie, Résultat thérapeutique, Sujet âgé, Études transversales.

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Anxiety (epidemiology), Anxiety (etiology), Blood Glucose (metabolism), Cross-Sectional Studies (MeSH), Diabetes Mellitus, Type 2 (complications), Diabetes Mellitus, Type 2 (epidemiology), Diabetes Mellitus, Type 2 (psychology), Diabetes Mellitus, Type 2 (therapy), Female (MeSH), Glycated Hemoglobin A (metabolism), Humans (MeSH), Hypoglycemia (epidemiology), Hypoglycemia (etiology), Hypoglycemia (psychology), Internationality (MeSH), Male (MeSH), Middle Aged (MeSH), Patient Reported Outcome Measures (MeSH), Quality of Life (MeSH), Self Report (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , metabolism : Blood Glucose, Glycated Hemoglobin A.
- complications : Diabetes Mellitus, Type 2.
- epidemiology : Anxiety, Diabetes Mellitus, Type 2, Hypoglycemia.
- etiology : Anxiety, Hypoglycemia.
- psychology : Diabetes Mellitus, Type 2, Hypoglycemia.
- therapy : Diabetes Mellitus, Type 2.
- Adult, Aged, Cross-Sectional Studies, Female, Humans, Internationality, Male, Middle Aged, Patient Reported Outcome Measures, Quality of Life, Self Report, Treatment Outcome.

Abstract

OBJECTIVE

PANORAMA, a nine-country cross-sectional type 2 diabetes study, investigated factors associated with quality of life (QoL), health status, and other patient-reported outcome measures (PROMs).

RESEARCH DESIGN AND METHODS

Patients were randomly or consecutively selected from primary/secondary care. PROMs included the Audit of Diabetes-Dependent Quality of Life (ADDQoL) (generic QoL item and average weighted impact [AWI] scores), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (patient- and physician-completed), Hypoglycemia Fear Survey-II worry subscale, and the EuroQoL-5 Dimension visual analog scale (EQ-VAS) measuring patient-reported health. Multivariable linear regression analyses determined predictors of each PROM including patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin.

RESULTS

In 5,813 patients, mean PROM scores indicated that generic QoL approximated "good" (0.93); perceived impact of diabetes on QoL was negative (AWI -1.69). Treatment satisfaction exceeded physicians' estimates (patient-reported: 29.76; physician-estimated: 27.75), but so did patients' perceived frequency of hypo-/hyperglycemia. Worry about hypoglycemia (13.27) was apparent. Intensifying treatments to three oral agents or insulin regimens predicted worse QoL (AWI

CONCLUSIONS

Predictors for different PROMs differed markedly and provided insights for understanding and improving these important outcomes. Intensive treatment regimens had significant negative associations with all PROMs, except the EQ-VAS health status measure. The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control.

DOI: 10.2337/dc16-2655
PubMed: 29183910

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000971
to stream Main, to step Curation: 000971

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.</title>
<author><name sortKey="Bradley, Clare" sort="Bradley, Clare" uniqKey="Bradley C" first="Clare" last="Bradley">Clare Bradley</name>
<affiliation wicri:level="4"><nlm:affiliation>Health Psychology Research Unit, Royal Holloway, University of London, Egham, U.K. c.bradley@rhul.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Health Psychology Research Unit, Royal Holloway, University of London, Egham</wicri:regionArea>
<orgName type="university">Université de Londres</orgName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eschwege, Eveline" sort="Eschwege, Eveline" uniqKey="Eschwege E" first="Eveline" last="Eschwège">Eveline Eschwège</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Pablos Velasco, Pedro" sort="De Pablos Velasco, Pedro" uniqKey="De Pablos Velasco P" first="Pedro" last="De Pablos-Velasco">Pedro De Pablos-Velasco</name>
<affiliation wicri:level="1"><nlm:affiliation>Dr. Negrin Hospital, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Dr. Negrin Hospital, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria</wicri:regionArea>
<wicri:noRegion>Las Palmas de Gran Canaria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Parhofer, Klaus G" sort="Parhofer, Klaus G" uniqKey="Parhofer K" first="Klaus G" last="Parhofer">Klaus G. Parhofer</name>
<affiliation wicri:level="4"><nlm:affiliation>Medical Department 4, Grosshadern, Klinikum der Universität München, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medical Department 4, Grosshadern, Klinikum der Universität München, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Simon, Dominique" sort="Simon, Dominique" uniqKey="Simon D" first="Dominique" last="Simon">Dominique Simon</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Cardiometabolism and Nutrition, Hôpital de la Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institute of Cardiometabolism and Nutrition, Hôpital de la Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Diabetes Department, Hôpital de la Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Diabetes Department, Hôpital de la Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vandenberghe, Hans" sort="Vandenberghe, Hans" uniqKey="Vandenberghe H" first="Hans" last="Vandenberghe">Hans Vandenberghe</name>
<affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Uccle, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>AstraZeneca, Uccle</wicri:regionArea>
<wicri:noRegion>Uccle</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gonder Frederick, Linda" sort="Gonder Frederick, Linda" uniqKey="Gonder Frederick L" first="Linda" last="Gönder-Frederick">Linda Gönder-Frederick</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Virginia Health System, Charlottesville, VA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Virginie</region>
</placeName>
<wicri:cityArea>University of Virginia Health System, Charlottesville</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29183910</idno>
<idno type="pmid">29183910</idno>
<idno type="doi">10.2337/dc16-2655</idno>
<idno type="wicri:Area/Main/Corpus">000971</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000971</idno>
<idno type="wicri:Area/Main/Curation">000971</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000971</idno>
<idno type="wicri:Area/Main/Exploration">000971</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.</title>
<author><name sortKey="Bradley, Clare" sort="Bradley, Clare" uniqKey="Bradley C" first="Clare" last="Bradley">Clare Bradley</name>
<affiliation wicri:level="4"><nlm:affiliation>Health Psychology Research Unit, Royal Holloway, University of London, Egham, U.K. c.bradley@rhul.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Health Psychology Research Unit, Royal Holloway, University of London, Egham</wicri:regionArea>
<orgName type="university">Université de Londres</orgName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eschwege, Eveline" sort="Eschwege, Eveline" uniqKey="Eschwege E" first="Eveline" last="Eschwège">Eveline Eschwège</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Pablos Velasco, Pedro" sort="De Pablos Velasco, Pedro" uniqKey="De Pablos Velasco P" first="Pedro" last="De Pablos-Velasco">Pedro De Pablos-Velasco</name>
<affiliation wicri:level="1"><nlm:affiliation>Dr. Negrin Hospital, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Dr. Negrin Hospital, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria</wicri:regionArea>
<wicri:noRegion>Las Palmas de Gran Canaria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Parhofer, Klaus G" sort="Parhofer, Klaus G" uniqKey="Parhofer K" first="Klaus G" last="Parhofer">Klaus G. Parhofer</name>
<affiliation wicri:level="4"><nlm:affiliation>Medical Department 4, Grosshadern, Klinikum der Universität München, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medical Department 4, Grosshadern, Klinikum der Universität München, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Simon, Dominique" sort="Simon, Dominique" uniqKey="Simon D" first="Dominique" last="Simon">Dominique Simon</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Cardiometabolism and Nutrition, Hôpital de la Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institute of Cardiometabolism and Nutrition, Hôpital de la Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Diabetes Department, Hôpital de la Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Diabetes Department, Hôpital de la Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vandenberghe, Hans" sort="Vandenberghe, Hans" uniqKey="Vandenberghe H" first="Hans" last="Vandenberghe">Hans Vandenberghe</name>
<affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Uccle, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>AstraZeneca, Uccle</wicri:regionArea>
<wicri:noRegion>Uccle</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gonder Frederick, Linda" sort="Gonder Frederick, Linda" uniqKey="Gonder Frederick L" first="Linda" last="Gönder-Frederick">Linda Gönder-Frederick</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Virginia Health System, Charlottesville, VA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Virginie</region>
</placeName>
<wicri:cityArea>University of Virginia Health System, Charlottesville</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Diabetes care</title>
<idno type="eISSN">1935-5548</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Anxiety (epidemiology)</term>
<term>Anxiety (etiology)</term>
<term>Blood Glucose (metabolism)</term>
<term>Cross-Sectional Studies (MeSH)</term>
<term>Diabetes Mellitus, Type 2 (complications)</term>
<term>Diabetes Mellitus, Type 2 (epidemiology)</term>
<term>Diabetes Mellitus, Type 2 (psychology)</term>
<term>Diabetes Mellitus, Type 2 (therapy)</term>
<term>Female (MeSH)</term>
<term>Glycated Hemoglobin A (metabolism)</term>
<term>Humans (MeSH)</term>
<term>Hypoglycemia (epidemiology)</term>
<term>Hypoglycemia (etiology)</term>
<term>Hypoglycemia (psychology)</term>
<term>Internationality (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Patient Reported Outcome Measures (MeSH)</term>
<term>Quality of Life (MeSH)</term>
<term>Self Report (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Anxiété (épidémiologie)</term>
<term>Anxiété (étiologie)</term>
<term>Autorapport (MeSH)</term>
<term>Diabète de type 2 (complications)</term>
<term>Diabète de type 2 (psychologie)</term>
<term>Diabète de type 2 (thérapie)</term>
<term>Diabète de type 2 (épidémiologie)</term>
<term>Femelle (MeSH)</term>
<term>Glycémie (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Hypoglycémie (psychologie)</term>
<term>Hypoglycémie (épidémiologie)</term>
<term>Hypoglycémie (étiologie)</term>
<term>Hémoglobine A glycosylée (métabolisme)</term>
<term>Internationalité (MeSH)</term>
<term>Mesures des résultats rapportés par les patients (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Qualité de vie (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Études transversales (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term>
<term>Glycated Hemoglobin A</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Anxiety</term>
<term>Diabetes Mellitus, Type 2</term>
<term>Hypoglycemia</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anxiety</term>
<term>Hypoglycemia</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Diabète de type 2</term>
<term>Glycémie</term>
<term>Hémoglobine A glycosylée</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Diabète de type 2</term>
<term>Hypoglycémie</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
<term>Hypoglycemia</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Anxiété</term>
<term>Diabète de type 2</term>
<term>Hypoglycémie</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Anxiété</term>
<term>Hypoglycémie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cross-Sectional Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Internationality</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Patient Reported Outcome Measures</term>
<term>Quality of Life</term>
<term>Self Report</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Autorapport</term>
<term>Femelle</term>
<term>Humains</term>
<term>Internationalité</term>
<term>Mesures des résultats rapportés par les patients</term>
<term>Mâle</term>
<term>Qualité de vie</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Études transversales</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>PANORAMA, a nine-country cross-sectional type 2 diabetes study, investigated factors associated with quality of life (QoL), health status, and other patient-reported outcome measures (PROMs).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESEARCH DESIGN AND METHODS</b>
</p>
<p>Patients were randomly or consecutively selected from primary/secondary care. PROMs included the Audit of Diabetes-Dependent Quality of Life (ADDQoL) (generic QoL item and average weighted impact [AWI] scores), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (patient- and physician-completed), Hypoglycemia Fear Survey-II worry subscale, and the EuroQoL-5 Dimension visual analog scale (EQ-VAS) measuring patient-reported health. Multivariable linear regression analyses determined predictors of each PROM including patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>In 5,813 patients, mean PROM scores indicated that generic QoL approximated "good" (0.93); perceived impact of diabetes on QoL was negative (AWI -1.69). Treatment satisfaction exceeded physicians' estimates (patient-reported: 29.76; physician-estimated: 27.75), but so did patients' perceived frequency of hypo-/hyperglycemia. Worry about hypoglycemia (13.27) was apparent. Intensifying treatments to three oral agents or insulin regimens predicted worse QoL (AWI </p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Predictors for different PROMs differed markedly and provided insights for understanding and improving these important outcomes. Intensive treatment regimens had significant negative associations with all PROMs, except the EQ-VAS health status measure. The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29183910</PMID>
<DateCompleted><Year>2018</Year>
<Month>07</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-5548</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>41</Volume>
<Issue>2</Issue>
<PubDate><Year>2018</Year>
<Month>02</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes care</Title>
<ISOAbbreviation>Diabetes Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.</ArticleTitle>
<Pagination><MedlinePgn>267-276</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/dc16-2655</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE">PANORAMA, a nine-country cross-sectional type 2 diabetes study, investigated factors associated with quality of life (QoL), health status, and other patient-reported outcome measures (PROMs).</AbstractText>
<AbstractText Label="RESEARCH DESIGN AND METHODS">Patients were randomly or consecutively selected from primary/secondary care. PROMs included the Audit of Diabetes-Dependent Quality of Life (ADDQoL) (generic QoL item and average weighted impact [AWI] scores), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (patient- and physician-completed), Hypoglycemia Fear Survey-II worry subscale, and the EuroQoL-5 Dimension visual analog scale (EQ-VAS) measuring patient-reported health. Multivariable linear regression analyses determined predictors of each PROM including patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin.</AbstractText>
<AbstractText Label="RESULTS">In 5,813 patients, mean PROM scores indicated that generic QoL approximated "good" (0.93); perceived impact of diabetes on QoL was negative (AWI -1.69). Treatment satisfaction exceeded physicians' estimates (patient-reported: 29.76; physician-estimated: 27.75), but so did patients' perceived frequency of hypo-/hyperglycemia. Worry about hypoglycemia (13.27) was apparent. Intensifying treatments to three oral agents or insulin regimens predicted worse QoL (AWI <i>P</i>
 < 0.01). Insulin alone use predicted worse QoL (generic <i>P</i>
 < 0.02; AWI <i>P</i>
 < 0.001) and hypoglycemia worry (<i>P</i>
 < 0.007). No treatment had significant associations with EQ-VAS health status.</AbstractText>
<AbstractText Label="CONCLUSIONS">Predictors for different PROMs differed markedly and provided insights for understanding and improving these important outcomes. Intensive treatment regimens had significant negative associations with all PROMs, except the EQ-VAS health status measure. The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control.</AbstractText>
<CopyrightInformation>© 2017 by the American Diabetes Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bradley</LastName>
<ForeName>Clare</ForeName>
<Initials>C</Initials>
<Identifier Source="ORCID">0000-0002-4079-0364</Identifier>
<AffiliationInfo><Affiliation>Health Psychology Research Unit, Royal Holloway, University of London, Egham, U.K. c.bradley@rhul.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eschwège</LastName>
<ForeName>Eveline</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>INSERM, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Pablos-Velasco</LastName>
<ForeName>Pedro</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Dr. Negrin Hospital, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Parhofer</LastName>
<ForeName>Klaus G</ForeName>
<Initials>KG</Initials>
<AffiliationInfo><Affiliation>Medical Department 4, Grosshadern, Klinikum der Universität München, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Simon</LastName>
<ForeName>Dominique</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition, Hôpital de la Pitié-Salpêtrière, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Diabetes Department, Hôpital de la Pitié-Salpêtrière, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vandenberghe</LastName>
<ForeName>Hans</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>AstraZeneca, Uccle, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gönder-Frederick</LastName>
<ForeName>Linda</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>University of Virginia Health System, Charlottesville, VA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00916513</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>11</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Diabetes Care</MedlineTA>
<NlmUniqueID>7805975</NlmUniqueID>
<ISSNLinking>0149-5992</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2018 May;6(10):187</RefSource>
<PMID Version="1">29951509</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2018 Jun;6(11):220</RefSource>
<PMID Version="1">30023383</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>12</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>10</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>12</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>7</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>11</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29183910</ArticleId>
<ArticleId IdType="pii">dc16-2655</ArticleId>
<ArticleId IdType="doi">10.2337/dc16-2655</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Belgique</li>
<li>Espagne</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Bavière</li>
<li>District de Haute-Bavière</li>
<li>Grand Londres</li>
<li>Virginie</li>
<li>Île-de-France</li>
</region>
<settlement><li>Londres</li>
<li>Munich</li>
<li>Paris</li>
</settlement>
<orgName><li>Université Louis-et-Maximilien de Munich</li>
<li>Université de Londres</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Bradley, Clare" sort="Bradley, Clare" uniqKey="Bradley C" first="Clare" last="Bradley">Clare Bradley</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Eschwege, Eveline" sort="Eschwege, Eveline" uniqKey="Eschwege E" first="Eveline" last="Eschwège">Eveline Eschwège</name>
</region>
<name sortKey="Simon, Dominique" sort="Simon, Dominique" uniqKey="Simon D" first="Dominique" last="Simon">Dominique Simon</name>
<name sortKey="Simon, Dominique" sort="Simon, Dominique" uniqKey="Simon D" first="Dominique" last="Simon">Dominique Simon</name>
</country>
<country name="Espagne"><noRegion><name sortKey="De Pablos Velasco, Pedro" sort="De Pablos Velasco, Pedro" uniqKey="De Pablos Velasco P" first="Pedro" last="De Pablos-Velasco">Pedro De Pablos-Velasco</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Parhofer, Klaus G" sort="Parhofer, Klaus G" uniqKey="Parhofer K" first="Klaus G" last="Parhofer">Klaus G. Parhofer</name>
</region>
</country>
<country name="Belgique"><noRegion><name sortKey="Vandenberghe, Hans" sort="Vandenberghe, Hans" uniqKey="Vandenberghe H" first="Hans" last="Vandenberghe">Hans Vandenberghe</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Virginie"><name sortKey="Gonder Frederick, Linda" sort="Gonder Frederick, Linda" uniqKey="Gonder Frederick L" first="Linda" last="Gönder-Frederick">Linda Gönder-Frederick</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000831 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000831 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    AutomedicationFrancoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29183910
   |texte=   Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29183910" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AutomedicationFrancoV1

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 15 15:24:36 2021. Site generation: Mon Mar 15 15:32:03 2021

	Serveur d'exploration sur l'automédication dans le monde francophone
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'automédication dans le monde francophone

Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.

Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki